The effect of dose on the bioavailability of oral etoposide
- 1 March 1986
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 16 (2) , 178-181
- https://doi.org/10.1007/bf00256172
Abstract
Summary The bioavailability of orally administered etoposide varies considerably. The effect of dose on bioavailability has not previously been investigated. In this study six patients were each treated with oral etoposide at doses of 200, 400, and 600 mg, and the pharmacokinetics determined. Each patient acted as his own control. The area under the plasma concentration-time curve (AUC) was proportionately greatest at the lowest dose. Doubling the dose from 200 mg to 400 mg increased AUC by only 50%, and a further increase of only 2.2% occurred at a dose of 600 mg. These data show nonlinear bioavailability of etoposide within the range in clinical use and may explain the variable results of reported studies. The data may have important implications for chemotherapy regimens with oral etoposide.Keywords
This publication has 16 references indexed in Scilit:
- High-performance liquid chromatography of etoposide in plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 1985
- STRIPE: An interactive computer program for the analysis of drug pharmacokineticsJournal of Pharmacological Methods, 1983
- Pharmacokinetics of VP16-213 given by different administration methodsCancer Chemotherapy and Pharmacology, 1982
- Current development of podophyllotoxinsCancer Chemotherapy and Pharmacology, 1982
- VP16-213 (etoposide). A critical review of its activity.1982
- VP-16-213 (etoposide): The mandrake root from Issyk-KulThe American Journal of Medicine, 1982
- ETOPOSIDE: A NEW ANTI-CANCER AGENTThe Lancet, 1981
- The Epipodophyllotoxin Derivatives VM-26 and VP-16-213, 1976–1979, a ReviewPublished by Springer Nature ,1980
- Etoposide (VP-16-213)Cancer Treatment Reviews, 1979
- A comparison of the mechanisms of action of VP-16-213 and podophyllotoxin.1977